A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard University, has filed to raise up to $100m in an initial public offering on the Nasdaq Global Market that would represent an exit for chemical producer Lonza, internet and technology group Alphabet and care provider Mass General Brigham. The company had raised $170m as of a $110m series B round in May 2021 featuring Lonza and corporate venturing units GV and Mass General Brigham Ventures.
Trifacta, a US-based data…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
